Basecamp Wealth Advisors’s Astria Therapeutics ATXS Stock Holding History

Basecamp Wealth Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-97	Closed	-$1.27K	–	2025
2025 Q4	$1.27K	Buy	+97	New	+$1.16K	﹤0.01%	1447

Basecamp Wealth Advisors's ATXS Position: Q1 2026 in Review

Basecamp Wealth Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 97 shares — an estimated $1.27K sold.

Basecamp Wealth Advisors first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $1.27K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Basecamp Wealth Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Basecamp Wealth Advisors sold 97 Astria Therapeutics shares in Q1 2026, an estimated $1.27K.
Basecamp Wealth Advisors first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Basecamp Wealth Advisors's Astria Therapeutics position peaked at $1.27K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q1 2026, filed 24 Jun 2026.